$67.95 0.95 (+1.42%)
2/13/2012 11:54 AM

Amgen, Inc. (NASDAQ:AMGN)

CAPS Rating: 4 out of 5

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

Results 1 - 20 of 334 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar eblasy (< 20) Submitted: 12/21/2011 11:21:38 AM : Outperform Start Price: $61.99 AMGN Score: -0.16

This company will outperform the S&P because is was practicaly the original Biotech company. If there is going to be an advance in Biotechnology, this is the company to look for it in. Even though you shouldn't go for the big companies, this is the time to pick because there is going to be an advance in biotech very soon.

Recs

1
Member Avatar portefeuille (99.81) Submitted: 12/15/2011 9:24:07 PM : Outperform Start Price: $47.45 AMGN Score: -10.77

There are currently 650 AMGN shares in my "fund" with break-even of around 59.13 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

Recs

0
Member Avatar GMoneyCaps (96.79) Submitted: 12/13/2011 7:37:39 PM : Outperform Start Price: $56.84 AMGN Score: +9.32

12/13

Recs

0
Member Avatar gameguru (29.81) Submitted: 11/1/2011 11:25:07 AM : Outperform Start Price: $55.31 AMGN Score: +12.81

AMGN is a canary stock - cheep, cheep, cheep. Well-positioned as a trading stock given its volatility.

Recs

0
Member Avatar StockDocStan (< 20) Submitted: 9/9/2011 2:52:49 PM : Outperform Start Price: $53.54 AMGN Score: +9.89

Biotech will soon lead the market, and it dominates my intermediate-term portfolio. Amgen is going to get legs again with new growth products, then LOOKOUT!

Recs

0
Member Avatar KittyLitterClump (75.16) Submitted: 4/18/2011 12:44:40 PM : Outperform Start Price: $54.22 AMGN Score: +21.32

Could a dividend be in the future?
I smell one coming......

Recs

0
Member Avatar healthcarevalue (96.64) Submitted: 3/28/2011 1:52:32 PM : Outperform Start Price: $51.93 AMGN Score: +28.10

Good size company at market cap of 49.30 billion. Price/earnings of 11.04 is pretty low relative to industry. Total long term debt is a bit much at 13.36 billion, but when taken in consideration with its market cap, and its total cash of 17.42 billion, this seems alright. Attractive collaborative arrangements with Pfizer and GlaxoSmithKline. In addition, return on invested capital (ROIC) is impressive, at over 22 percent.

Recs

0
Member Avatar UninformedPicks (34.51) Submitted: 3/16/2011 12:32:45 PM : Outperform Start Price: $52.18 AMGN Score: +23.81

Looks fundamentally undervalued

Recs

0
Member Avatar Whizkid81 (53.11) Submitted: 3/2/2011 11:39:27 AM : Outperform Start Price: $50.93 AMGN Score: +30.39

Great value...Biotechnology stock trading well below it s 52 week high

Recs

0
Member Avatar dataguru61 (73.39) Submitted: 2/26/2011 7:20:48 PM : Outperform Start Price: $51.57 AMGN Score: +30.05

AMGN's Product line continues to expand.. no reason to bet against this winner!

Recs

0
Member Avatar syljtffreedom (95.33) Submitted: 2/23/2011 2:09:39 PM : Outperform Start Price: $50.69 AMGN Score: +30.83

good cash balances

Recs

0
Member Avatar UpPeriscope1 (< 20) Submitted: 2/22/2011 8:32:26 PM : Underperform Start Price: $51.08 AMGN Score: -30.47

Underperform

Recs

0
Member Avatar rofgile (23.18) Submitted: 2/15/2011 5:41:56 PM : Outperform Start Price: $52.51 AMGN Score: +28.17

Biotech watchlist

Recs

0
Member Avatar Bigdog2020 (68.43) Submitted: 1/14/2011 5:19:16 PM : Underperform Start Price: $55.52 AMGN Score: -17.80

Will need to buy a company to enrich near-term pipeline outside of Xgeva/Prolia which won't contribute much to the bottom line for the next year or so... this will leave revenues flat. Entering "big pharma"-like phase... not a growth stock in the near term...

Recs

0
Member Avatar RevelationMan (< 20) Submitted: 1/13/2011 3:20:23 AM : Outperform Start Price: $55.84 AMGN Score: +16.66

Go long and strong and grab anything under $60.

Recs

0
Member Avatar getoutngo (< 20) Submitted: 12/7/2010 2:02:08 PM : Underperform Start Price: $52.38 AMGN Score: -20.37

If 2011's revenue and earnings are stagnant, where exactly is the growth coming from to propel the shares in the next 12 months?

Recs

0
Member Avatar EpiphanyStock (43.14) Submitted: 12/6/2010 4:26:12 PM : Outperform Start Price: $52.79 AMGN Score: +19.72

a biotech stock trading at big pharma prices.

Recs

0
Member Avatar crossmpls007 (60.01) Submitted: 11/5/2010 2:46:57 PM : Outperform Start Price: $54.40 AMGN Score: +14.53

hunch

Recs

0
Member Avatar targetphil3 (< 20) Submitted: 9/7/2010 7:37:50 PM : Outperform Start Price: $51.65 AMGN Score: +8.57

banking on upcoming phase III results

Recs

0
Member Avatar jncgator (< 20) Submitted: 8/22/2010 12:21:52 PM : Outperform Start Price: $51.58 AMGN Score: +6.26

The best buy in biotech

Featured Broker Partners


Advertisement